CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
LY2603618 +1 moredrug
Likely dose
LY2603618 150 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00988858
NCT00988858Phase 2Completed
CompareCT.gov

A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Eli Lilly and Company·interventional·Posted Oct 2, 2009·Updated Sep 17, 2019

In Brief

A Phase 2 clinical trial evaluating LY2603618 and Pemetrexed for Non Small Cell Lung Cancer. Completed, enrolled 55 participants across 13 sites in 4 countries.

Detailed Summary

The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesItaly, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2012
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.8 years ago

Interventions

LY2603618drug

150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression

Pemetrexeddrug

500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression